A clear map of where cancer care is heading — leadership, data, capital, access & therapy
New therapies are outpacing access. Capital is flowing into dedicated cancer facilities. And leadership rosters are turning over at a striking pace, with entirely new roles appearing on the org chart.
This Becker's market briefing from reads each shift through the lens of where attention, budget and decision-making are actually moving across cancer care in 2026.
Drawing on Becker's reporting, it tracks 65 cancer-center leadership moves logged so far this year, an 11,000-patient biomarker repository inside one community-based system, and a $175 million commitment to a single new cancer center.
Inside the briefing:
This Becker's market briefing from reads each shift through the lens of where attention, budget and decision-making are actually moving across cancer care in 2026.
Drawing on Becker's reporting, it tracks 65 cancer-center leadership moves logged so far this year, an 11,000-patient biomarker repository inside one community-based system, and a $175 million commitment to a single new cancer center.
Inside the briefing:
- Why the cancer-center C-suite is reshaping around commercialization, payer strategy, digital and cell therapy — and what the new titles signal
- How biomarker repositories, genomics and AI are moving from research pilots into core operating infrastructure
- Where systems are placing capital bets on dedicated cancer real estate and tumor-centric care models
- How access, coverage and equity are becoming the gating variables for what gets adopted
The same shifts mapped here drive the agenda at Becker's Fall Oncology Executive Summit, Nov. 4-5, 2026, at Swissotel Chicago.
Please fill out the form to download the briefing.
Please fill out the form to download the whitepaper.